Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSI-L/dMMR

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

MSI-H/dMMR (182)

MSI-H/dMMR + TMB-H (8)

MSI-H/dMMR + TMB-L (5)

PTEN mutation + MSI-H/dMMR (5)

MSI-H/dMMR + POLE mutation (4)

ARID1A mutation + MSI-H (3)

MSI-H/dMMR + MLH1 deletion + PMS2 deletion (3)

MSI-H/dMMR + TMB-H + PD-L1 negative (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)

MSI-L/dMMR + KRAS G12V (2)

B2M mutation + MSI-H/dMMR (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

JAK1 mutation + MSI-H/dMMR (1)

JAK2 mutation + MSI-H/dMMR (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR + TMB-H (1)

MSH6 mutation + MLH1 mutation + MSI-H (1)

MSI-H + HER-2 amplification (1)

MSI-H + MSH2 expression + MSH6 expression (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + HER-2 mutation (1)

MSI-H/dMMR + KDR overexpression (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MSI-H/dMMR + MLH1 negative + PMS2 negative (1)

MSI-H/dMMR + NTRK1 fusion (1)

MSI-H/dMMR + NTRK2 fusion (1)

MSI-H/dMMR + NTRK3 fusion (1)

MSI-H/dMMR + PD-1 expression + CD8 positive (1)

MSI-H/dMMR + RAS mutation (1)

MSI-H/dMMR + TP53 mutation (1)

NOTCH1 mutation + TMB-L + MSI-L/dMMR (1)

PD-L1 expression + MSI-H/dMMR (1)

PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)

SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)

TMB-H + PD-L1 expression + MSI-L/dMMR (1)

AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)

MSI-H/dMMR + RAS wild-type (0)

MSI-L/dMMR + SMAD4 mutation (0)

PIK3CA mutation + TMB-L + MSI-L/dMMR (0)

MSI-H/dMMR (182)

MSI-H/dMMR + TMB-H (8)

MSI-H/dMMR + TMB-L (5)

PTEN mutation + MSI-H/dMMR (5)

MSI-H/dMMR + POLE mutation (4)

ARID1A mutation + MSI-H (3)

MSI-H/dMMR + MLH1 deletion + PMS2 deletion (3)

MSI-H/dMMR + TMB-H + PD-L1 negative (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)

MSI-L/dMMR + KRAS G12V (2)

B2M mutation + MSI-H/dMMR (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

JAK1 mutation + MSI-H/dMMR (1)

JAK2 mutation + MSI-H/dMMR (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR + TMB-H (1)

MSH6 mutation + MLH1 mutation + MSI-H (1)

MSI-H + HER-2 amplification (1)

MSI-H + MSH2 expression + MSH6 expression (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + HER-2 mutation (1)

MSI-H/dMMR + KDR overexpression (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MSI-H/dMMR + MLH1 negative + PMS2 negative (1)

MSI-H/dMMR + NTRK1 fusion (1)

MSI-H/dMMR + NTRK2 fusion (1)

MSI-H/dMMR + NTRK3 fusion (1)

MSI-H/dMMR + PD-1 expression + CD8 positive (1)

MSI-H/dMMR + RAS mutation (1)

MSI-H/dMMR + TP53 mutation (1)

NOTCH1 mutation + TMB-L + MSI-L/dMMR (1)

PD-L1 expression + MSI-H/dMMR (1)

PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)

SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)

TMB-H + PD-L1 expression + MSI-L/dMMR (1)

AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)

MSI-H/dMMR + RAS wild-type (0)

MSI-L/dMMR + SMAD4 mutation (0)

PIK3CA mutation + TMB-L + MSI-L/dMMR (0)

›

MSI-L/dMMR	Small Intestinal Carcinoma	MSI-L/dMMR	Small Intestinal Carcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
MSI-L/dMMR	Colorectal Cancer	MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
MSI-L/dMMR	Penile Cancer	MSI-L/dMMR	Penile Cancer	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4